Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe revision on the page updated from v3.6.0 to v3.6.3, representing a minor update to the page version without altering core study details.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now shows that no participants are being recruited, and adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) along with a revision note to reflect a page update.SummaryDifference0.3%

- Check29 days agoChange DetectedFooter revision label updated from v3.5.4 to v3.5.5, indicating a backend/page-system update. This does not modify the study data or visible content.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study location list was updated to add Taebuk, South Korea (28644) and remove Jungbuk, South Korea (28644); the page revision was updated from v3.5.3 to v3.5.4.SummaryDifference0.4%

- Check72 days agoChange DetectedThis updates the ClinicalTrials.gov page footer to reflect a newer software/version revision (from v3.5.2 to v3.5.3).SummaryDifference0.0%

- Check80 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.